Same Day, Different Strategies: How Lilly's $6.5 Billion Houston Groundbreaking and Novo's Capital Markets Day Reveal Diverging Paths in the Oral GLP-1 Manufacturing Race

Key takeaways

• On 21 September 2026, Eli Lilly broke ground on a $6.5 billion API manufacturing facility in Houston, Texas, and Novo Nordisk held its Capital Markets Day in London — on the same day, with manufacturing at the centre of both events.
• Lilly's Foundayo (orforglipron) is a small molecule, not a peptide; the company argues this makes it considerably more scalable than peptide-based oral formulations.
• Novo pledged to expand oral GLP-1 capacity to serve ten times the patients it currently reaches, underpinned by investments in Denmark, Ireland, North Carolina, and the US more broadly.
• The divergence matters for the peptide research sector: Novo's oral Wegovy (oral semaglutide) remains a peptide-based product, creating sustained demand for solid-dose peptide manufacturing infrastructure that Lilly's strategy deliberately sidesteps.
• Investor sentiment towards the two companies diverged sharply in the days following the announcements, with Novo's stock falling under continued pressure while Lilly's manufacturing commitments were read as evidence of competitive staying power.

The 21 September moment

Researchers and procurement professionals who follow the GLP-1 sector had an unusually information-dense Monday last week. In Houston, Lilly executives broke ground on what the company described as its fifth US active pharmaceutical ingredient (API) site announced since 2020 and one of ten US manufacturing locations committed to during that period. Eli Lilly's investor relations statement confirmed the site will produce Foundayo (orforglipron), its "first synthetic oral GLP-1 medicine, along with other small-molecule medicines and advanced therapeutics."

Simultaneously, in London, Novo Nordisk CEO Maziar Mike Doustdar was addressing investors at the company's Capital Markets Day, pledging that Novo would "scale our oral manufacturing to 10 times more than the patients we serve today," according to BioSpace's account of the event. The symmetry was not lost on industry observers.

Lilly: small-molecule manufacturing at scale

The Houston facility occupies roughly 240 acres at Generation Park and will manufacture APIs for Foundayo alongside oligonucleotides and other advanced therapeutics, according to Pharma Manufacturing. The site is expected to employ more than 600 people and forms part of Lilly's broader commitment of more than $50 billion in domestic medicine manufacturing investment since 2020.

The chemistry distinction is commercially significant. BIC Magazine's coverage of the groundbreaking noted that "Foundayo is a small molecule rather than a peptide; small molecules are manufactured using more well-established technologies and therefore can be more readily scalable." Lilly has made this argument repeatedly, and the Houston investment is its most tangible expression of that thesis: conventional chemical synthesis routes, scaled industrially, without the yield constraints that characterise solid-phase peptide synthesis (SPPS).

Foundayo received FDA approval for weight management and is currently under regulatory review in more than 40 countries, with a full global rollout targeted for 2027. Lilly's investor release also noted that the facility will focus on advanced therapeutics "that were not within reach even a few years ago," including oligonucleotides — signalling that Houston is conceived as a multi-generation asset rather than a single-product site.

Pharma Manufacturing's market commentary reported that Lilly CEO Dave Ricks stated on the groundbreaking day that one-third of new oral GLP-1 pill patients are now taking Foundayo as the company ramps up production, suggesting the commercial launch ramp — which was slower out of the gate than Novo's in the spring — is gaining momentum.

Novo: peptide-based oral semaglutide and the 10× pledge

Novo's position is structurally different. Its oral Wegovy product is a formulation of semaglutide, a 31-amino-acid GLP-1 analogue — a peptide, not a small molecule. Manufacturing the active ingredient requires SPPS or biotechnological production at large scale. The tabletting process itself also demands careful management of the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), which must be co-formulated at high ratios with the peptide API.

At the Capital Markets Day held in London on 21 September, Novo's strategic ambitions for 2030 were set out formally. According to the Globe Newswire announcement, targets include launching more than five multi-blockbuster products by 2030, delivering over 150 billion DKK in risk-adjusted pipeline sales in 2035, and — the headline manufacturing figure — scaling capacity to serve ten times more people with obesity on oral GLP-1. Stocktitan's summary of the event translated that ambition into a concrete patient count: 15 million patients on oral obesity therapies by the end of the decade, up from the roughly 1.5 million currently on the Wegovy pill.

The manufacturing infrastructure supporting that pledge is already being assembled. Pharma Manufacturing reported that Novo is building a new $9 billion API facility at its Kalundborg, Denmark site and has invested $4.1 billion to expand its fill-and-finish facility in Clayton, North Carolina. European Pharmaceutical Review reported a €432 million upgrade of Novo's tabletting facility in Monksland, Athlone, Ireland, which the company described as a "critical hub" for markets outside the United States; construction there is expected to complete gradually between the end of 2027 and 2028.

At current scale, oral Wegovy has been taken up rapidly. Life Science Daily News reported more than five million cumulative US prescriptions within 30 weeks of launch and weekly US prescriptions exceeding 265,000 in mid-July 2026 — demand that has already strained the supply network and contributed to one-off restructuring costs of approximately DKK 3 billion recognised in Novo's half-year results.

Investor reaction and market positioning

The Capital Markets Day was not uniformly well received. CNBC's 25 September analysis noted that "Wall Street so far isn't convinced by Novo's road map," with investors unimpressed by revenue growth targets that matched industry-peer averages rather than the outsized rates associated with Wegovy's early years. Novo's share price had already been under pressure following the CagriSema clinical loss to Lilly's Zepbound earlier in the year. The CMD was therefore as much a stabilisation exercise as a forward strategy communication.

STAT News characterised Doustdar's approach as seeking to reassure investors that Novo would "regain its momentum in the coming years," including plans to diversify beyond diabetes and obesity and to be "more active within business development." That framing — an acknowledgement of investor concern about GLP-1 concentration risk — mirrors a broader debate about whether Novo's product mix is sufficiently diversified ahead of semaglutide patent expirations in key markets in the early 2030s.

Implications for the peptide supply chain

For procurement professionals and contract research organisations sourcing peptide APIs or following the CDMO consolidation wave, the divergence between these two strategies carries practical significance.

Novo's approach sustains and extends demand for peptide manufacturing infrastructure. Each oral Wegovy tablet requires peptide API; a tenfold increase in patient capacity means a corresponding scale of SPPS or bioprocess demand across Novo's supply network. This is the same underlying logic that drove Samsung Biologics' approximately CHF 1.46 billion ($1.8 billion) acquisition of PolyPeptide Group — whose acceptance period runs through 12 October 2026 — and CordenPharma's acquisition of AmbioPharm, both reflecting the view that commercial-scale peptide synthesis capacity cannot be built quickly from scratch.

Lilly's small-molecule route, by contrast, reduces its dependence on SPPS capacity for its core oral product but does not reduce peptide demand from its injectable portfolio. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist peptide and remains a major volume product; retatrutide, the triple agonist in Phase 3 development, is also a peptide. The Houston site does not serve those products, which are produced at Lilly's other API locations.

The net effect is that the oral GLP-1 manufacturing race is creating two structurally distinct demand curves for the peptide sector: one driven by the scale-up of injectable and peptide-based oral formulations (primarily Novo), and one driven by small-molecule alternatives that increasingly compete for the same patient population (primarily Lilly). Research-use suppliers and CDMOs would be prudent to monitor which demand curve their primary customers sit on, as commercial dynamics will differ materially over the next three to five years.

This briefing draws on publicly available company announcements, investor releases, and trade press reporting as of 26 September 2026. It does not constitute investment advice.